MedTrace Logo

Study of Serine Supplementation to Protect Vision in MacTel

NCT07342439 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-01-15

No results posted yet for this study

Summary

The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional changes of the retina in people with MacTel type 2. The main questions it aims to answer are:

* Does serine slow the progression of MacTel?
* Is long-term serine supplementation safe in people with MacTel? Researchers will compare serine to a placebo (a look-alike substance that contains no drug) to see if serine works to slow the progression of MacTel.

Participants will:

* Take serine or a placebo twice a day for 24 months
* Visit the clinic once every 6 months for eye exam, eye imaging and blood tests
* Keep a diary of their symptoms, missed doses, and changes in medications

Conditions

  • Macular Telangiectasia Type 2 (MacTel)

Interventions

DRUG

L-serine

L-serine powder administered twice daily

OTHER

Placebo

Placebo powder administered twice daily

Sponsors & Collaborators

  • The Lowy Medical Research Institute Limited

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2029-11-30
Completion
2030-02-28
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Germany
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07342439 on ClinicalTrials.gov